Disclaimer
The stock market is subject to significant volatility and inherent risks. Investing in stocks involves potential losses and is not guaranteed to generate profits. Prices of stocks can fluctuate unpredictably, We do not give any buy/sell tips. This article is for Educational purposes only.
The Sai Life Sciences IPO is a book-built issue with a total size of ₹3,042.62 crores, comprising a fresh issue of ₹950 crores (1.73 crore shares) and an offer for sale (OFS) of ₹2,092.62 crores (3.81 crore shares). Investors can subscribe to the Sai Life Sciences IPO from December 11, 2024, to December 13, 2024.
The Sai Life Sciences IPO allotment status will be finalized on December 16, 2024, and the shares are expected to be listed on BSE and NSE on December 18, 2024.
The IPO price band is set at ₹522 to ₹549 per share. The minimum lot size for retail investors is 27 shares (₹14,823). For sNII, it is 378 shares (₹207,522), and for bNII, it is 1,836 shares (₹1,007,964).
Kotak Mahindra Capital, Jefferies India, Morgan Stanley, and IIFL Securities are the book-running lead managers, while KFin Technologies is the registrar for the Sai Life Sciences IPO.
Based in Bollaram, IPO is a prominent pharmaceutical company with strong financials reflected in its turnover. Questions about the IPO owner and its robust business model attract investor interest.
| Field | Details |
|---|---|
| IPO Date | December 11, 2024 to December 13, 2024 |
| Listing Date | December 18, 2024 |
| Face Value | ₹1 per share |
| Price Band | ₹522 to ₹549 per share |
| Lot Size | 27 Shares |
| Total Issue Size | 55,421,123 shares (aggregating up to ₹3,042.62 Cr) |
| Fresh Issue | 17,304,189 shares (aggregating up to ₹950.00 Cr) |
| Offer for Sale | 38,116,934 shares of ₹1 (aggregating up to ₹2,092.62 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 190,685,340 |
| Share Holding Post Issue | 207,989,529 |
| Event | Date |
|---|---|
| IPO Open Date | Wednesday, December 11, 2024 |
| IPO Close Date | Friday, December 13, 2024 |
| Basis of Allotment | Monday, December 16, 2024 |
| Initiation of Refunds | Tuesday, December 17, 2024 |
| The credit of Shares to Demat | Tuesday, December 17, 2024 |
| Listing Date | Wednesday, December 18, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on December 13, 2024 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹192,699 |
| S-HNI (Min) | 14 | 378 | ₹207,522 |
| S-HNI (Max) | 67 | 1,809 | ₹993,141 |
| B-HNI (Min) | 68 | 1,836 | ₹1,007,964 |
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 1,66,26,336 (30%) | NA |
| QIB Shares Offered | 1,10,84,225 (20%) | NA |
| NII (HNI) Shares Offered | 83,13,168 (15%) | |
| bNII > ₹10L | 55,42,113 (10%) | 14,661 |
| NII < ₹10L | 27,71,056 (5%) | 7,330 |
| Retail Shares Offered | 1,93,97,392 (35%) | 7,18,421 |
| Total Shares Offered | 5,54,21,121 (100%) |
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Revenue | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| Net Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Reserves and Surplus | 1,025.44 | 953.99 | 867.43 | 859.17 |
| Total Borrowing | 764.49 | 710.16 | 699.23 | 751.32 |
| Amount in ₹ Crore | ||||
The Sai Life Sciences IPO presents a compelling investment opportunity for retail and institutional investors alike. With a price band set between ₹522 and ₹549 per share, a balanced mix of fresh issues and an offer for sale (OFS), and robust financials reflected in the IPO turnover, the company is well-positioned for significant growth in the pharmaceutical and life sciences industry. Based in Bollaram, IPO has earned a reputation for excellence and innovation, making its IPO highly anticipated in the market.
Investors closely monitoring the Sai Life Sciences IPO allotment status and its eventual listing on BSE and NSE are optimistic about its market performance. The IPO's minimum lot sizes cater to both retail investors and high-net-worth individuals, offering investment flexibility starting from ₹14,823. Platforms like IPO Watch and details in the Sai Life Sciences IPO RHP provide valuable insights for potential subscribers.
The involvement of leading book-running managers such as Kotak Mahindra Capital, Jefferies India, Morgan Stanley, and IIFL Securities, alongside KFin Technologies as the registrar, ensures a seamless IPO process. Queries about the Sai Life Sciences owner and its impressive track record continue to attract investor attention.
As one of the key IPOs coming in December 2024, the Sai Life Sciences IPO symbolizes both innovation and trust in India's growing pharmaceutical sector. For those looking to invest in a promising venture, the Sai Life Sciences IPO offers the perfect combination of stability, growth potential, and market appeal.
